A French post-market Observational/Non-interventional Study of the BioMatrix Flex™ and BioMatrix NeoFlex™drug eluting stents with 6-month DAPT.
ClinicalTrials.gov ID: NCT01289002
Sponsor
Study objectives
The purpose of this registry is to capture clinical data of the BioMatrix™ and BioMatrix Flex™ (Biolimus A9™-Eluting) stent systems in relation to safety and effectiveness.
Primary endpoints
Major adverse cardiac and cerebrovascular events (MACCE) in the overall population, defined as composite of all-cause death, cerebrovascular accidents, non-fatal myocardial infarction or clinically-driven target vessel revascularization at 6 months.
CERC Services
- Full Services
Countries
Austria, Czechia, Denmark, France, Germany, Ireland, Jordan, Latvia, Lithuania, Morocco, Poland, Portugal, Russia, Spain, Switzerland, United Kingdom
Number of investigational sites
69
Number of patients
5652
